P122 Conducting federated treatment effectiveness analyses for systemic therapies in atopic dermatitis across country borders: methodological considerations from the DREAM TO TREAT AD project
Elizaveta Gribaleva(King's College London), Carsten Flohr(King's College London), Niels Steen Krogh(Synlab Czech (Czechia)), Ahmet Akkoç(Synlab Czech (Czechia)), Simon Francis Thomsen(University of Copenhagen), Louise A. A. Gerbens(Amsterdam UMC Location University of Amsterdam), Maria Oberländer Christensen(University of Copenhagen), Abaigeal Jackson(Vhi Healthcare), Thomas Werfel(Medizinische Hochschule Hannover), Axel Hertzschuch(University Hospital Carl Gustav Carus), Erman Güler(Pfizer (United States)), Lara Cutlar(University College Dublin), Bolaji Coker(King's College London), Jochen Schmitt(University Hospital Carl Gustav Carus), Phyllis I. Spuls, Alan D. Irvine(Trinity College Dublin), Thomas Birkner(University Hospital Carl Gustav Carus), Con Hennessy(University College Dublin), Stephan Weidinger(University Hospital Schleswig-Holstein), David Prieto‐Merino(London School of Hygiene & Tropical Medicine), Benoit Raymond(Pfizer (United Kingdom)), Anne Grete Frøstrup(Pfizer (United Kingdom))
Cited by 0
Related Papers
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
|Nature Genetics|2012|1k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Tight junction defects in patients with atopic dermatitis
|Journal of Allergy and Clinical Immunology|2010|741